×
Friday, October 3, 2025

Feds Eye Partial Pretrial Ruling In Regeneron FCA Case - Law360

"naturally or foreseeably" caused providers to present false claims for its macular degeneration drug Eylea, arguing that it does not need to prove the tougher "but-for causation" standard for its theory of false certification. . . .

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.

A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.



Read Full Story: https://news.google.com/rss/articles/CBMimgFBVV95cUxQdFRTc1owR0g0d19UYkJjQk9r...